Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4523510 Target Snapshot

Cholesterol 24-hydroxylase · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
211Compounds
27Assays
4Approved Drugs
102.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Cholesterol 24-hydroxylase shows late clinical disease relevance led by Lennox-Gastaut syndrome. 4 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q9Y6A2. Start with Lennox-Gastaut syndrome, then reuse UniProt Q9Y6A2 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with Lennox-Gastaut syndrome, then reuse UniProt Q9Y6A2 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 1 linked drug
Open source guide
Disease program
Lennox-Gastaut syndrome

Cholesterol 24-hydroxylase shows late clinical disease relevance led by Lennox-Gastaut syndrome. 4 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with Lennox-Gastaut syndrome because it currently carries late clinical support. Linked drugs include SOTICLESTAT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Late clinical Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Cholesterol 24-hydroxylase as ChEMBL target CHEMBL4523510, mapped to UniProt Q9Y6A2. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Cholesterol 24-hydroxylase
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL4523510
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q9Y6A2
Cholesterol 24-hydroxylase
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Cholesterol 24-hydroxylase is the right protein anchor across sources, using UniProt Q9Y6A2 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why Lennox-Gastaut syndrome is currently framed as late clinical support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameCholesterol 24-hydroxylase
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtQ9Y6A2
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelCholesterol 24-hydroxylase
UniProt AccessionQ9Y6A2
Component TypeProtein
Sequence Length500 aa

Cholesterol 24-hydroxylase

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Cholesterol 24-hydroxylase, mapped to UniProt Q9Y6A2. Sequence length is 500 aa.

Mapped IDQ9Y6A2
Review nameCholesterol 24-hydroxylase
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Late clinical Open Targets-ready proxy

Cholesterol 24-hydroxylase shows late clinical disease relevance led by Lennox-Gastaut syndrome. 4 more disease programs remain visible in the same review block.

Late clinical Phase III
Lennox-Gastaut syndrome
1 linked drug · 1 direct · 1 efficacy
Linked drugSOTICLESTAT
Clinical signal Phase II
complex regional pain syndrome
1 linked drug · 1 direct · 1 efficacy
Linked drugSOTICLESTAT
Clinical signal Phase I
epilepsy
1 linked drug · 1 direct · 1 efficacy
Linked drugSOTICLESTAT
Clinical signal Phase I
liver disease
1 linked drug · 1 direct · 1 efficacy
Linked drugSOTICLESTAT
Clinical signal Phase I
Seizure
1 linked drug · 1 direct · 1 efficacy
Linked drugSOTICLESTAT
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with Lennox-Gastaut syndrome because it currently carries late clinical support. Linked drugs include SOTICLESTAT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseLennox-Gastaut syndrome
Strongest levelLate clinical
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

4
Approved
1
Phase III
1
Phase II
Assay Mix

Activity Type Distribution

IC5068.0
KI6.0
KD28.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5279173 9.0 IC50 1.0 Preclinical
CHEMBL5288661 8.62 IC50 2.4 Preclinical
CHEMBL5276973 8.57 IC50 2.7 Preclinical
CHEMBL5282804 8.37 IC50 4.3 Preclinical
CHEMBL5271033 8.36 IC50 4.4 Preclinical
CHEMBL5269674 8.33 IC50 4.7 Preclinical
CHEMBL4547685 8.31 IC50 4.9 Preclinical
CHEMBL5289771 8.31 IC50 4.9 Preclinical
CHEMBL4587543 8.27 IC50 5.4 Preclinical
CHEMBL5284673 8.21 IC50 6.1 Preclinical
Distribution

pChEMBL Value Distribution

9
5.0
9
5.5
6
6.0
5
6.5
17
7.0
18
7.5
20
8.0
2
8.5
1
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

VORICONAZOLE
CHEMBL638
Approved 2002
Properties Compare Identifier
EFAVIRENZ
CHEMBL223228
Approved 1998
Properties Compare Identifier
Assay Landscape

Assay Landscape

27
Total Assays
78
Tested Compounds
2
Assay Types
Binding — 24 assays, 78 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 14 51 6.8
single protein format 8 4 7.0
cell-based format 2 23 7.4
ADME — 3 assays, 3 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 2 0 —
single protein format 1 3 7.2

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine